Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y (2008) Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 70(2):657–665. https://doi.org/10.1016/j.ejpb.2008.05.019

Article  CAS  PubMed  Google Scholar 

Li C, Zhao X, Deng C, Wang C, Wei N, Cui J (2014) Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect. Int J Parm 460(1–2):165–172. https://doi.org/10.1016/j.ijpharm.2013.10.023

Article  CAS  Google Scholar 

Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8–14. https://doi.org/10.2165/00003495-199700544-00004

Article  CAS  PubMed  Google Scholar 

Lim HJ, Masin D, Madden TD, Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566–573

CAS  PubMed  Google Scholar 

Milla P, Dosio F, Cattel L (2012) PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 13(1):105–119. https://doi.org/10.2174/138920012798356934

Article  CAS  PubMed  Google Scholar 

Wang CX, Li CL, Zhao X, Yang HY, Wei N, Li YH, Zhang L, Zhang L (2010) Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride. Yao Xue Xue Bao 45(12):1565–1569

CAS  PubMed  Google Scholar 

Yang J, Shi Y, Li C, Gui L, Zhao X, Liu P, Han X, Song Y, Li N, Du P, Zhang S (2014) Phase I clinical trial of pegylated liposomal mitoxantrone PLM-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer Chemother Pharmacol 74(3):637–646. https://doi.org/10.1007/s00280-014-2523-8

Article  CAS  PubMed  Google Scholar 

Cai Q, Xia Y, Wang L, Huang H, Wang J, Cai J, Tian X (2023) Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK/T cell lymphoma: a phase Ib/II clinical trial. Blood 142:4470. https://doi.org/10.1182/blood-2023-188430

Article  Google Scholar 

Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56(5):747–756. https://doi.org/10.2165/00003495-199856050-00001

Article  CAS  PubMed  Google Scholar 

Morotti M, Valenzano Menada M, Venturini PL, Ferrero S (2011) Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. Expert Opin Drug Metab Toxicol 7(6):707–720. https://doi.org/10.1517/17425255.2011.570330

Article  CAS  PubMed  Google Scholar 

Fulton MD, Najahi-Missaoui W (2023) Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci 24(7):6615. https://doi.org/10.3390/ijms24076615

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Y, Ouyang W, Zhang J, Chen M, Qing D, Zeng Q, Huang Y, Hao C, Jia R, Wu Z, Ni S, Huang Y (2023) Pharmacokinetics, safety profiles and efficacy of liposomal mitoxantrone hydrochloride in patients with relapse/refractory advanced lymphoma. Chemo Open Access 11:175. https://doi.org/10.35248/2167-7700.23.11.175

Article  Google Scholar 

Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL (1985) Disposition of mitoxantrone in cancer patients. Cancer Res 45(4):1879–1884

CAS  PubMed  Google Scholar 

Svensson RJ, Jonsson EN (2022) Efficient and relevant stepwise covariate model building for pharmacometrics. CPT Pharmacometrics Syst Pharmacol 11(9):1210–1222. https://doi.org/10.1002/psp4.12838

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jonsson EN, Nyberg J (2022) A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses. CPT Pharmacometrics Syst Pharmacol 11(6):673–686. https://doi.org/10.1002/psp4.12790

Article  CAS  PubMed  PubMed Central  Google Scholar 

Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35(2):185–202. https://doi.org/10.1007/s10928-007-9081-1

Article  PubMed  PubMed Central  Google Scholar 

Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481–504. https://doi.org/10.1023/a:1012299115260

Article  CAS  PubMed  Google Scholar 

Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3(2):101–107. https://doi.org/10.1007/BF00174156

Article  CAS  PubMed  Google Scholar 

Richard B, Launay-Iliadis MC, Iliadis A, Just-Landi S, Blaise D, Stoppa AM, Viens P, Gaspard MH, Maraninchi D, Cano JP (1992) Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. Br J Cancer 65(3):399–404. https://doi.org/10.1038/bjc.1992.81

Article  CAS  PubMed  PubMed Central  Google Scholar 

Launay MC, Iliadis A, Richard B (1989) Population pharmacokinetics of mitoxantrone performed by a NONMEM method. J Pharm Sci 78(10):877–880. https://doi.org/10.1002/jps.2600781020

Article  CAS  PubMed  Google Scholar